Last reviewed · How we verify
NCT04118114
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
Phase 2 trial testing PRL3-zumab in Gastric Cancer in 30 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | National Cancer Centre, Singapore |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 3 September 2019 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- PRL3-zumab — full drug profile →
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
National Cancer Centre, Singapore
Who can join
21 and older, any sex, with Gastric Cancer or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy. Approximately 30 patients will be recruited with \~10 gastric cancers and \~10 hepatocellular carcinomas. Patients who have received at least 1 dose of PRL3-ZUMAB will be evaluable for toxicity and efficacy. PRL3-ZUMAB will be given IV every 2 weeks for up to 12 infusions in the absence of unmanageable toxicities or disease progression. Patients who are benefitting from the treatment may continue on PRL3-ZUMAB beyond 12 infusions with the agreement of the study drug provider. PRL3-ZUMAB at the RP2D in tumour types enriched for known PRL-3 expression for efficacy and tolerability will be evaluated. There will also be in depth molecular profiling of tissues in patients who have an objective response or prolonged disease stabilization to identify predictive/selection biomarkers as well as evaluation of the oncogenic signaling modulation and immunomodulation by PRL3-ZUMAB and its potential for future combination with other targeted therapies or immunotherapy.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A, Biber G, Barda-Saad M. · · 2020 · cited 103× · PMID 32153582 · DOI 10.3389/fimmu.2020.00275 -
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.
Stanford SM, Bottini N. · · 2023 · cited 80× · PMID 36693907 · DOI 10.1038/s41573-022-00618-w -
Targeting Phosphatases and Kinases: How to Checkmate Cancer.
Turdo A, D'Accardo C, Glaviano A, Porcelli G, et al · · 2021 · cited 40× · PMID 34778245 · DOI 10.3389/fcell.2021.690306 -
PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types.
Chia PL, Ang KH, Thura M, Zeng Q. · · 2023 · cited 21× · PMID 37064866 · DOI 10.7150/thno.79265 -
From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.
Zhou Y, Yao Z, Lin Y, Zhang H. · · 2024 · cited 8× · PMID 39065585 · DOI 10.3390/pharmaceutics16070888 -
Development and characterization of nanobodies that specifically target the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3) and impact its interaction with a known binding partner, CNNM3.
Smith CN, Kihn K, Williamson ZA, Chow KM, et al · · 2023 · cited 6× · PMID 37220097 · DOI 10.1371/journal.pone.0285964 -
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP, Thura M, Gupta A, Tan SH, et al · · 2023 · cited 4× · PMID 37674627 · DOI 10.1016/j.omto.2023.08.006 -
The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.
Park DJ, Thura M, Chiu VK, Vicuna B, et al · · 2025 · cited 3× · PMID 40345181 · DOI 10.1016/j.xcrm.2025.102120
Verify or expand the search:
- PubMed search for NCT04118114
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PRL3-zumab
Trials testing the same drug.
- NCT04452955 — A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors · Phase 2 · active not recruiting
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other National Cancer Centre, Singapore trials
Trials by the same sponsor.
- NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
- NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
- NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
- NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
- NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04118114 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
- Last refreshed: 11 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04118114.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing